The Cleveland Clinic Foundation

July 30, 2021

The assistant professor at Cleveland Clinic discussed key factors to consider when choosing repurposed drugs that could show max potential in treating Alzheimer disease.

July 27, 2021

The therapy, already FDA-approved for individuals with pulmonary artery disease, was significantly associated with reduced likelihood of Alzheimer disease in both the 65-74 year range and those older than 75 years.

July 24, 2021

Investigators observed declines in delayed verbal recall in 20% to 30% of individuals who underwent a dominant temporal lobe resection for treatment of epilepsy.

July 21, 2021

The duo from Cleveland Clinic stressed the reasons for conducting real-world data assessing migraine treatments and why it can lead to the ultimate goal of treatment optimization.

July 17, 2021

The neurologist from Cleveland Clinic discussed the importance of studying real-world outcomes in patients with migraine using CGRPs such as eptinezumab.

July 11, 2021

The headache fellow at Cleveland Clinic outlined the design and reasoning for a new study assessing nerve blocks to treat COVID-19 headache.